Cargando…
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196531/ https://www.ncbi.nlm.nih.gov/pubmed/34118966 http://dx.doi.org/10.1186/s13046-021-02001-w |
_version_ | 1783706708372094976 |
---|---|
author | Dou, Zhihui Zhao, Dapeng Chen, Xiaohua Xu, Caipeng Jin, Xiaodong Zhang, Xuetian Wang, Yupei Xie, Xiaodong Li, Qiang Di, Cuixia Zhang, Hong |
author_facet | Dou, Zhihui Zhao, Dapeng Chen, Xiaohua Xu, Caipeng Jin, Xiaodong Zhang, Xuetian Wang, Yupei Xie, Xiaodong Li, Qiang Di, Cuixia Zhang, Hong |
author_sort | Dou, Zhihui |
collection | PubMed |
description | Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy. |
format | Online Article Text |
id | pubmed-8196531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81965312021-06-15 Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation Dou, Zhihui Zhao, Dapeng Chen, Xiaohua Xu, Caipeng Jin, Xiaodong Zhang, Xuetian Wang, Yupei Xie, Xiaodong Li, Qiang Di, Cuixia Zhang, Hong J Exp Clin Cancer Res Review Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy. BioMed Central 2021-06-12 /pmc/articles/PMC8196531/ /pubmed/34118966 http://dx.doi.org/10.1186/s13046-021-02001-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Dou, Zhihui Zhao, Dapeng Chen, Xiaohua Xu, Caipeng Jin, Xiaodong Zhang, Xuetian Wang, Yupei Xie, Xiaodong Li, Qiang Di, Cuixia Zhang, Hong Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title | Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title_full | Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title_fullStr | Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title_full_unstemmed | Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title_short | Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
title_sort | aberrant bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196531/ https://www.ncbi.nlm.nih.gov/pubmed/34118966 http://dx.doi.org/10.1186/s13046-021-02001-w |
work_keys_str_mv | AT douzhihui aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT zhaodapeng aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT chenxiaohua aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT xucaipeng aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT jinxiaodong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT zhangxuetian aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT wangyupei aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT xiexiaodong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT liqiang aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT dicuixia aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation AT zhanghong aberrantbclxsplicingincancerfrommolecularmechanismtotherapeuticmodulation |